Singapore, Sept. 9 -- Kelun-Biotech has reported positive interim Phase II results for SKB378/WIN378, an investigational ultra-long-acting monoclonal antibody targeting thymic stromal lymphopoietin, as partner Windward Bio advances the programme into Phase III development.

The Phase II portion of the global POLARIS-1 study enrolled 147 patients with uncontrolled moderate-to-severe asthma.

An interim analysis of the first 98 patients showed sustained effects on lung function and inflammatory biomarkers through week 24 following a single dose.

SKB378/WIN378 is a fully human monoclonal antibody engineered for improved potency, extended half-life and silenced effector function.

The candidate uses a differentiated binding mechanism targeti...